Media headlines about Auris Medical (NASDAQ:EARS) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Auris Medical earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 47.5857002044789 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

Auris Medical (EARS) traded down $0.02 during trading hours on Friday, reaching $0.44. The company’s stock had a trading volume of 477,600 shares, compared to its average volume of 489,104. The company has a debt-to-equity ratio of -14.04, a current ratio of 1.86 and a quick ratio of 1.86. Auris Medical has a 1 year low of $0.38 and a 1 year high of $1.39.

Separately, Zacks Investment Research cut Auris Medical from a “buy” rating to a “hold” rating in a research report on Wednesday, October 11th.

COPYRIGHT VIOLATION WARNING: This story was reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.watchlistnews.com/auris-medical-ears-getting-somewhat-positive-media-coverage-accern-reports/1766371.html.

About Auris Medical

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Insider Buying and Selling by Quarter for Auris Medical (NASDAQ:EARS)

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.